Figure S1A. The correlation between variables - both quantitative and qualitative variables -
and the principal dimensions at baseline (week 0) S1B. The correlation between variables - both quantitative and qualitative variables - and the principal dimensions at week 14
The first principal dimension accounts for as much of the variability in the data as possible, and each succeeding dimension accounts for as much of the remaining variability as possible.
Values between 0.3 and 1.0 are considered as important in contributing to the dimension.
Abbreviations: WBC, white blood cells; PLTS, platelets; CRP, C-reactive protein; BMI, body mass index; Dim, dimension; Group, treatment group to which to which the patients belonged.
A
T
B
T
Table S1. The clot-lysis and inflammatory parameters of the 28 clinical non-remitters, before and after induction therapy
Abbreviations:VDZ, vedolizumab; IFX, infliximab; MP,methylprednisolone; NA, not applicable; CRP, C-reactive protein; WBC, white blood cells. aValues are expressed as medians. bPAI-1 antigen, 50%CLT, AUC and amplitude are expressed relative to the values of the PP of HC
(=100%). cPatients in the combination group in whom therapy with methylprednisolone was discontinued before week 14.
VDZ IFX IFX/VDZ – MPc MP
N 12 10 4 2
Before After Before After Before After Before After
AUC (%) 184 203 127 122 211 105 291 243
CRP (mg/L) 7.9 12.0 1.5 1.4 51.4 10.7 291.3 116.8
Platelets (109/L) 279 316 316 266 306 352 375 539
WBC (109/L) 8.2 8.4 7.9 7.3 9.0 6.8 15.8 9.1
Albumin (g/L) 42 40 43 42 41 41 35 30
Hemoglobin (g/dL) 13 13 13 13 13 14 14 12
Amplitude (%) 139 137 110 102 184 135 217 207
Tmax (min) 30 24 30 32 30 18 24 32
Fibronectin (µg/mL) 410 443 379 405 266 418 293 434
50%CLT (%) 122 135 114 108 100 85 125 111
PAI-1 antigen (%) 93 109 76 90 104 91 163 183